|
|
News Breaks | | | | November 12, 2012 | | 07:04 EDT |  | CTIX | Cellceutix signs agreement for clinical trial in Europe on new psoriasis drug
Cellceutix has signed an agreement with a European Union, or EU, clinical site for a Proof-of-Concept, or PoC, trial of Prurisol, the company's lead drug candidate for the treatment of psoriasis. The trial, a double blind study, is planned for the first quarter of 2013 and will include patient dosing over a 30-day period with follow up visits over the next 30 days. Cellceutix decided on this protocol after discussions with pharmaceutical industry executives and believes this is the quickest path to evaluate the efficacy of Prurisol in humans with the objective of bringing it to market and creating greater shareholder value. | |
|
News For CTIX From The Last 14 Days Check below for free stories on CTIX the last two weeks. |
|
|
| May 15, 2013 | | 07:36 EDT |  | CTIX | Three Part Advisors to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
